Who predicted the Biden administration would limit distribution of the life-saving monoclonal antibodies for COVID patients? We did. And when we say “we”, we mean the American people who are suffering under COVID and this inept President.

“The Food and Drug Administration (FDA) on Monday significantly restricted the use of a pair of monoclonal antibody treatments for COVID-19 because they are ineffective against the omicron variant.”

Not to say “I told you so, but uhhhh…I told you so.” Four months ago, to be precise when Biden and DeSantis were going media rounds after Biden took over the supply and distribution of Regeneron monoclonal antibodies

The FDA added a little twist Monday. Why would they do such a thing?

“[The] FDA noted that ‘it’s highly unlikely that COVID-19 patients seeking care in the U.S. at this time are infected with a variant other than omicron.’”

Before we get all upset, it’s all about the variants. The FDA contends,

“…the therapies made by Eli Lilly and Regeneron should only be used in patients that have been infected with or exposed to a variant that is susceptible to the treatments.”

Sounds reasonable, right? Except that monoclonal antibody treatment recommended by America’s Frontline Doctors, those who are actually doing science regarding COVID, partly agree with the FDA.

“…the anti-SARS-CoV-2 monoclonal antibodies (mAbs) bamlanivimab plus etesevimab, casirivimab plus imdevimab, and sotrovimab were the only therapies recommended by the Panel for nonhospitalized patients with mild to moderate COVID-19 who are at high risk of progressing to severe disease. The Omicron VOC, which has numerous mutations in the spike protein, is predicted to have markedly reduced susceptibility to bamlanivimab plus etesevimab and casirivimab plus imdevimab. Because sotrovimab is the only available anti-SARS-CoV-2 mAb with activity against the Omicron VOC, the Panel recently added a 3-day course of intravenous (IV) remdesivir as another treatment option for this group of patients.”

America’s Frontline Doctors panel of experts recommend sotrovimab against Omicron coupled with remdesivir. Sotrovimab is not a monoclonal antibody treatment being restricted by the FDA. We’ve got that going for us. Whew.

Got it. Here are where the questions get tough.

First,

Do I have this right: Does $VIR make roughly $1,333 on every sotrovimab dose? Just trying to understand the $GSK deal quickly.

— Matt (@MattBiotech) January 22, 2022

To the FDA, if we’re so concerned about the effectiveness of a treatment for COVID, why are we still being told vaccines are the best defense against COVID? We are on the verge of hearing the need for the fourth booster in less than a year of having the vaccine, with thousands of “breakthrough cases”. Oh yes, the little troll-man has spoken.

NEW – Dr. Fauci: “We may need to boost again.”pic.twitter.com/9vr6IUTFbN

— Disclose.tv (@disclosetv) January 23, 2022

Here’s a thought that has crossed everyone’s mind but those on Pfizer’s or Glaxo’s payroll in the FDA—the vaccines don’t work. If we’re going to take the position to withdraw medications because they don’t work—monoclonal antibodies according to the FDA—why aren’t we taking the same position when it comes to vaccines?

Great question.

Antibodies are zero risk. Proven. Can they say that about the shot? These frauds refuse to allow a variety of therapeutics and tell us what we CAN’T explore for treatment yet insist there’s a safe, one-size-fits all silver bullet “vaccine” we must take. https://t.co/3DKv5htSSP

— Chris Stigall (@ChrisStigall) January 25, 2022

It’s my job to create heartburn for unelected bureaucrats. You’re welcome.

Why does this guidance come from the FDA just four days after 30 House Republicans called on the FDA to rescind its guidance to use race in determining who receives monoclonal antibodies?

“Lawmakers say the agency’s guidelines direct medical providers to consider race in addition to medical risk factors when prescribing monoclonal antibodies, saying the guidance violates the 14^th Amendment.”

The FDA’s recent guidance that seeks to allocate life-saving monoclonal antibody treatments on the basis of race is WRONG.

This week I joined with my House colleagues in calling on the Biden Administration to rescind this guidance! https://t.co/vAr38lCJAb

— Congresswoman Tenney (@RepTenney) January 22, 2022

Going back to the availability of sotrovimab, we’re running out of that stuff too.

“Major hospitals in the New York region say they have stopped using monoclonal antibody therapies because they have run out of the one treatment that appears to be effective against the omicron variant of the coronavirus, leaving doctors without a vital tool to treat severely ill Covid-19 patients.”

Here’s another tough question, why is sotrovimab in short supply now? Did the FDA grab that supply too? Like they did in September? It’s a legit question since the FDA and Biden are hell-bent on politicizing, race-baiting and corrupting all things COVID and making zero effort to actually do science and provide truthful, health related guidelines, to the American public.

Bottom line, Biden’s FDA wants you to take an experimental vaccine that is proving to be ineffective against COVID. He’s used his powers to control the distribution of monoclonal antibodies the FDA claims is ineffective. Yet, the one thing the FDA and trusted doctors at America’s Frontline Doctors can agree on is the sotrovimab is effective against Omicron…and we’re running out of it and we aren’t sure why.

The handling of this pandemic by our government is pathetic and deadly.

Feature Photo Credit: Biden caricature by DonkeyHotey, cropped and modified, Attribution 2.0 Generic (CC BY 2.0)